Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Varticovski Website

Lyuba Varticovski, M.D.

Selected Publications

1)  Hager GL, Varticovski L.
Chromatin in time and space.
Biochim. Biophys. Acta. 1819: 631, 2012.
2)  Stavreva DA, Varticovski L, Hager GL.
Complex dynamics of transcription regulation.
Biochim. Biophys. Acta. 1819: 657-66, 2012.
3)  Dunlap SM, Chiao LJ, Nogueira L, Usary J, Perou CM, Varticovski L, Hursting SD.
Dietary Energy Balance Modulates Epithelial-to-Mesenchymal Transition and Tumor Progression in Murine Claudin-Low and Basal-like Mammary Tumor Models.
Cancer Prev Res (Phila). 5: 930-42, 2012.
4)  Kon M, Kiffin R, Koga H, Chapochnick J, Macian F, Varticovski L, Cuervo AM.
Chaperone-mediated autophagy is required for tumor growth.
Sci Transl Med. 3: 109ra117, 2011.
5)  Luchenko VL, Salcido CD, Zhang Y, Agama K, Komlodi-Pasztor E, Murphy RF, Giaccone G, Pommier Y, Bates SE, Varticovski L.
Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer.
Cell Cycle. 10: 3119-28, 2011.
6)  Salcido CD, Larochelle A, Taylor BJ, Dunbar CE, Varticovski L.
Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer.
Br. J. Cancer. 102: 1636-44, 2010.
7)  Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM, Mumau MD, Gottesman MM, Varticovski L, Ambudkar SV.
Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
J. Natl. Cancer Inst. 102: 1637-52, 2010.
8)  Ghobrial IM, Roccaro A, Hong F, Weller E, Rubin N, Leduc R, Rourke M, Chuma S, Sacco A, Jia X, Azab F, Azab AK, Rodig S, Warren D, Harris B, Varticovski L, Sportelli P, Leleu X, Anderson KC, Richardson PG.
Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.
Clin. Cancer Res. 16: 1033-41, 2010.
9)  Cerchietti LC, Lopes EC, Yang SN, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L, Shaknovich R, Bhalla KN, Chiosis G, Melnick A.
A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.
Nat. Med. 15: 1369-76, 2009.
10)  Pine SR, Ryan BM, Varticovski L, Robles AI, Harris CC.
Microenvironmental modulation of asymmetric cell division in human lung cancer cells.
Proc. Natl. Acad. Sci. U.S.A. 107: 2195-200, 2010.
11)  Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y, Wu N, de Stanchina E, White J, Gross SS, Ma Y, Varticovski L, Melnick A, Chiosis G.
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.
Proc. Natl. Acad. Sci. U.S.A. 106: 8368-73, 2009.
12)  Roccaro AM, Sacco A, Chen C, Runnels J, Leleu X, Azab F, Azab AK, Jia X, Ngo HT, Melhem MR, Burwick N, Varticovski L, Novina CD, Rollins BJ, Anderson KC, Ghobrial IM.
microRNA expression in the biology, prognosis, and therapy of Waldenstrom's macroglobulinemia.
Blood. 113: 4391-402, 2009.
13)  Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L.
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics.
Breast Cancer Res. 10: R10, 2008.
14)  Wright MH, Robles AI, Herschkowitz JI, Hollingshead MG, Anver MR, Perou CM, Varticovski L.
Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1.
Mol. Cancer. 7: 29, 2008.
15)  Calcagno AM, Fostel JM, To KK, Salcido CD, Martin SE, Chewning KJ, Wu CP, Varticovski L, Bates SE, Caplen NJ, Ambudkar SV.
Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.
Br. J. Cancer. 98: 1515-24, 2008.
16)  Bandyopadhyay U, Kaushik S, Varticovski L, Cuervo AM.
The Chaperone-Mediated Autophagy Receptor Organizes in Dynamic Protein Complexes at the Lysosomal Membrane.
Mol. Cell. Biol. 2008.
17)  Varticovski L, Hollingshead MG, Robles AI, Wu X, Cherry J, Munroe DJ, Lukes L, Anver MR, Carter JP, Borgel SD, Stotler H, Bonomi CA, Nunez NP, Hursting SD, Qiao W, Deng CX, Green JE, Hunter KW, Merlino G, Steeg PS, Wakefield LM, Barrett JC.
Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models.
Clin. Cancer Res. 13: 2168-77, 2007.
18)  Antony S, Agama KK, Miao ZH, Takagi K, Wright MH, Robles AI, Varticovski L, Nagarajan M, Morrell A, Cushman M, Pommier Y.
Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance.
Cancer Res. 67: 10397-405, 2007.
19)  Hursting SD, Nunez NP, Varticovski L, Vinson C.
The obesity-cancer link: lessons learned from a fatless mouse.
Cancer Res. 67: 2391-3, 2007.
20)  Heyerdahl SL, Rozenberg J, Jamtgaard L, Rishi V, Varticovski L, Akah K, Scudiero D, Shoemaker RH, Karpova TS, Day RN, McNally JG, Vinson C.
The arylstibonic acid compound NSC13746 disrupts B-ZIP binding to DNA in living cells.
Eur. J. Cell Biol. 89: 564-73, 2010.
21)  Koll TT, Feis SS, Wright MH, Teniola MM, Richardson MM, Robles AI, Bradsher J, Capala J, Varticovski L.
HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair.
Mol. Cancer Ther. 7: 1985-92, 2008.
22)  Robles AI, Varticovski L.
Harnessing genetically engineered mouse models for preclinical testing.
Chem. Biol. Interact. 171: 159-64, 2008.
23)  Nunez NP, Perkins SN, Smith NC, Berrigan D, Berendes DM, Varticovski L, Barrett JC, Hursting SD.
Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones.
Nutr Cancer. 60: 534-41, 2008.
24)  Shen JC, Unoki M, Ythier D, Duperray A, Varticovski L, Kumamoto K, Pedeux R, Harris CC.
Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin alpha1.
Cancer Res. 67: 2552-8, 2007.
25)  Antony S, Agama KK, Miao ZH, Hollingshead M, Holbeck SL, Wright MH, Varticovski L, Nagarajan M, Morrell A, Cushman M, Pommier Y.
Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity.
Mol. Pharmacol. 70: 1109-20, 2006.
26)  Robles AI, Wright MH, Gandhi B, Feis SS, Hanigan CL, Wiestner A, Varticovski L.
Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines.
Clin. Cancer Res. 12: 6547-56, 2006.
Click Here to View Collapsed Bibliography.

This page was last updated on 7/22/2012.